Nab-Paclitaxel, Cisplatin, and Gemcitabine Treatment Protocol for Pancreatic Cancer

This protocol has been investigated particularly for locally advanced or metastatic pancreatic adenocarcinoma, with promising results in some patient groups. The “TGen Triple,” or “triple-drug regimen,” is a three-drug chemotherapy combination used for advanced or metastatic pancreatic adenocarcinoma. It is named “TGen Triple” because it was first developed by the Translational Genomics Research Institute (TGen).

This three-drug regimen consists of:

• Nab-Paclitaxel: An agent that disrupts microtubule dynamics and stops cell division. It aims to suppress tumor growth and facilitate gemcitabine entry into cells.
• Cisplatin: Binds to DNA, forming crosslinks that inhibit DNA replication and trigger cell death. It aims to induce apoptosis through DNA damage.
• Gemcitabine: An antimetabolite that inhibits DNA synthesis by arresting the cell cycle. It aims to prevent tumor cell proliferation.

What Is the Aim of Treatment?

• Suppressing tumor cell proliferation: Gemcitabine inhibits DNA synthesis and arrests the cell cycle.
• Nab-paclitaxel disrupts microtubule dynamics and stops cell division.
• Cisplatin forms crosslinks in DNA strands, initiating apoptosis (programmed cell death).
• Targeting resistant cells through multiple mechanisms: Different mechanisms of action aim to destroy more tumor cells.
• Slowing metastatic spread and prolonging survival: Particularly in disease that has spread systemically, treatment aims to extend survival and improve quality of life.
• The rationale for this three-drug combination is that combining agents with different mechanisms can target tumor cells at different stages of their life cycle, overcome drug resistance, and achieve better outcomes in patients with DNA repair defects (such as BRCA1/2 mutations).
• The TGen Triple regimen remains investigational and is not a standard guideline-listed first-line treatment.

Dosage and Schedule

Although no definitive standard dosage or schedule has been established for the TGen Triple regimen (nab-paclitaxel + cisplatin + gemcitabine), the following schedule is based on clinical studies and case series:

• Day 1: Gemcitabine 1000 mg/m² (IV infusion over 30 minutes), nab-paclitaxel 125 mg/m² (IV infusion over 30–60 minutes), and cisplatin 25 mg/m² (IV infusion over 30–60 minutes)
• Day 8: Repeat the same medicines at the same doses.
• Day 15: Usually left as a rest day because of the risk of bone marrow suppression. However, treatment may also be scheduled on this day for some patients if their adverse-reaction profile permits, with very close monitoring of tolerability.
• Repeat the cycle every 21 days. A total of 4 to 6 cycles may be given; the number may be increased or decreased according to response, toxicity, and performance status.
• Antiemetic treatment (for nausea/vomiting): A three-drug combination such as a 5-HT3 antagonist, dexamethasone, and an NK1 antagonist is generally given.
• Colony-stimulating factors (G-CSF): May be used as needed to support patients at risk of leukopenia.
• Neuropathy and kidney function should be monitored regularly, particularly because of cisplatin and nab-paclitaxel.

Precautions

• Bone Marrow Suppression (Myelosuppression): Neutropenia, anemia, and thrombocytopenia are the most common hematological adverse reactions. They may cause infection risk, bleeding risk, and general weakness. A complete blood count is essential before each cycle. G-CSF (filgrastim) may be used to support patients with neutropenia.
• Kidney Function (Cisplatin-Related Nephrotoxicity): Cisplatin can cause cumulative kidney damage. Creatinine and eGFR should be monitored. Provide ample hydration, mannitol, and electrolyte support, particularly Mg²⁺ and K⁺.
• Peripheral Neuropathy: Prolonged nab-paclitaxel use in particular may damage nerve endings, causing numbness, tingling, or burning, especially in the hands and feet. Progressive worsening may require dose reduction.
• Nutritional Status and Loss of Appetite: This regimen may cause poor appetite, loss of taste, nausea, and weight loss. Nutritional supplements and dietitian support should be provided when needed.
• Cardiac Monitoring (Particularly in Older and High-Risk Patients): Cisplatin may rarely cause cardiac arrhythmias due to electrolyte imbalance. Potassium and magnesium deficiencies must be corrected.
• Severe Nausea and Vomiting: Cisplatin in particular has high emetogenic potential. A three-drug antiemetic combination containing a 5HT3 antagonist + NK1 antagonist + dexamethasone is recommended.
• Hepatic Toxicity: Gemcitabine may elevate liver enzymes. AST, ALT, and bilirubin should be monitored.
• Patients with Poor Performance Status: This combination carries a high risk of toxicity in patients with ECOG > 2. Dose modification or an alternative regimen should be considered based on age, comorbidities, and general condition.
• Patients with BRCA1/2 Mutations or DNA Repair Defects: Cisplatin-containing regimens may be more effective in this group. Genetic testing should identify the subgroup to inform a personalized treatment plan.

Adverse Reactions

• Neutropenia (low white blood cell count): 40–60%
• Leukopenia (reduced overall white blood cell count): 30–50%
• Anemia: 30–45%
• Thrombocytopenia (low platelet count): 15–25%
• Fatigue: 40–50%
• Peripheral neuropathy (numbness, tingling): 30–40%
• Hair loss (alopecia): 30–50%
• Loss of appetite and weight loss: 20–30%
• Nausea and vomiting: 30–40%
• Diarrhea and constipation: 20–25%
• Oral mucositis (mouth sores): 10–15%
• Low-grade fever and infection risk: 10–20%
• Impaired kidney function (cisplatin): 5–10%
• Elevated liver enzymes: 5–10%
• Electrolyte disturbances (particularly Mg and K): 10–15%
• Taste disturbances: 5–10%
• Conjunctivitis (eye irritation): <5%

Monitoring and Follow-Up

• A complete blood count should be performed before every cycle and weekly. Monitor for neutropenia, anemia, and thrombocytopenia.
• Kidney function, liver function, and electrolytes should be checked before every cycle.
• A neurological assessment should be performed at every outpatient visit, asking about finger numbness, tingling, and impaired balance.
• Tumor size and spread are monitored by CT or MRI every 2–3 cycles (every 6–9 weeks), with assessment according to RECIST criteria.
• ECOG performance status should be assessed at every visit. Appetite, weight loss, pain, and quality of life should be reviewed. If Grade 3–4 toxicity develops, the relevant agent's dose may be reduced by 25–50%. The interval between cycles may be extended if necessary. Agents causing irreversible toxicity may be removed from the protocol.